Table 1.
Basic characteristics of the included studies.
| Study (year) | Country | Study design | Sample size (n) | Metastasis case (n) | Histology | Histology subtypes | Follow-up period | Inflammation | NOS scores |
|---|---|---|---|---|---|---|---|---|---|
| Aggerholm-Pedersen et al. (2016) [30] | Denmark | Rs | 172 | 0 | BS | Chondrosarcoma (n = 63), Ewing/osteosarcoma (n = 109) | Median: 8.8 y Range: 4.3-19 y |
NA | 8 |
|
| |||||||||
| Liu et al. (2016) [31] | China | Rs | 162 | 19 | BS | Osteosarcoma (n = 162) | Median:28.2 m Range: 3.1-124.1 m |
Excluded | 8 |
|
| |||||||||
| Morhij et al. (2017) [32] | UK | Rs | 111 | 0 | STS/BS | Soft tissue sarcoma (n = 69), bone sarcoma (42) | Median:50 m Range: 34-78 m |
NA | 8 |
|
| |||||||||
| Li et al. (1) (2017) [34] | China | Rs | 216 | 32 | BS | Osteosarcoma (n = 216) | Median:31.5 m | Excluded | 9 |
|
| |||||||||
| Li et al. (2) (2017) [33] | China | Rs | 122 | 17 | BS | Ewing's sarcomas (n = 122) | Median:35 m | Excluded | 9 |
|
| |||||||||
| Maretty-Kongstad et al. (2017) [35] | Denmark | Rs | 888 | 0 | STS | Liposarcoma, UPS, leiomyosarcoma, dermatofibrosarcoma, synovial sarcoma, MPNST, and others | Mean: 5.7 y Range: 0.1-22 y |
NA | 7 |
|
| |||||||||
| Liang et al. (2017) [36] | China | Rs | 206 | NA | STS | MFH (n = 56), fibrosarcoma (n = 38), synovial sarcoma (n = 25), liposarcoma (n = 22), leiomyosarcoma (n = 9), rhabdomyosarcoma (n = 13), ASPS (n = 8), angiosarcoma (n = 6), MPNST (n = 8), mesenchymal chondrosarcoma (n = 7), others (n = 14) | Median:75.5 m Range: 8-136 m |
Excluded | 9 |
|
| |||||||||
| Tsuda et al. (2017) [37] | Japan | Rs | 202 | 0 | STS | UPS (n = 74), myofibrosaroma (n = 46), leiomyosarcoma (n = 19), dedifferentiated liposarcoma (n = 11), fibrosarcoma (n = 9), synovial sarcomas (n = 5), pleomorphic liposarcoma (n = 5), others (n = 33) | Mean: 58 m 95% CI: 52-62 m |
NA | 7 |
|
| |||||||||
| Jiang et al. (2017) [38] | China | Rs | 165 | 97 | STS | Fibrohistiocytic tumor (n = 41), undifferentiated sarcoma (n = 93), smooth muscle tumor (n = 10), skeletal muscle tumor (n = 17), adipocytic tumor (n = 3), fibroblastic/myofibroblastic tumor (n = 1) | Mean: 73.7 m Range: 17.2-533.8 m |
Excluded | 8 |
|
| |||||||||
| Sasaki et al. (2018) [39] | Japan | Rs | 103 | NA | STS | Soft tissue spindle cell sarcomas (n = 103) | 60.6 ± 39.6 m | NA | 7 |
|
| |||||||||
| Aggerholm-Pedersen et al. (2019) [40] | Denmark | Rs | 265 | 265 | STS/BS | STS (n = 202): UPS (n = 41), leiomyosarcoma (n = 31), liposarcoma (n = 27), synovial sarcoma (n = 27), MPNST (n = 15), others (n = 63) BS (n = 63): osteosarcoma (n = 28), Ewing's sarcoma (n = 8), chondrosarcoma (n = 19), others (n = 8) |
Median: 0.9 y | NA | 8 |
|
| |||||||||
| Xu et al. (2019) [41] | China | Rs | 83 | 9 | BS | Ewing's sarcomas (n = 83) | Mean: 20.3 m Range: 1-84 m |
Excluded | 8 |
Rs: retrospective study; STS: soft tissue sarcoma; BS: bone sarcoma; m: month; y: year; NA: not available; UPS: undifferentiated pleomorphic sarcoma; MPNST: malignant peripheral nerve sheath tumor; MFH: malignant fibrous histiocytoma; ASPS; alveolar soft part sarcoma.